Related Experiment Video

Updated: Jun 14, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.7K

In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo

Joseph H Friedman1

  • 1Butler Hospital/Alpert Medical School of Brown University, Providence, Rhode Island, USA (J.H.F.).

Annals of Internal Medicine
|September 2, 2024
PubMed
Abstract

Source Citation:

Meissner WG, Remy P, Giordana C, et al; LIXIPARK Study Group. Trial of lixisenatide in early Parkinson's disease. N Engl J Med. 2024;390:1176-1185. 38598572.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.7K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K

Related Experiment Videos

Last Updated: Jun 14, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.7K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.7K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K

Articles linked to this work by shared authors, journal, and citation graph.

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026

True vignettes: interesting, illustrative examples of behavioral abnormalities in people with Parkinson's disease.

Arquivos de neuro-psiquiatria·2026

Cross-Dataset Evaluation of an Automated Video-Based Model for Detecting Tardive Dyskinesia Using the Clinician's Tardive Inventory: Validation Study.

JMIR mental health·2026

Prodromal Peripheral Immune Cell Profile in Drug-Induced Parkinsonism Relative to Parkinson's Disease.

Movement disorders clinical practice·2025

Treating psychosis in people with Parkinson's disease.

Expert opinion on drug safety·2025

Episodic Coma in Lewy Body Disorders: An Observational Report.

The Neurohospitalist·2024

Overuse and False Restraint in Large Language Model Recommendations for Choosing Wisely Scenarios.

Annals of internal medicine·2026

Diagnosis and Treatment of Cardiovascular Conditions in Medicare Advantage In-Home Health Risk Assessments.

Annals of internal medicine·2026

Projected Effect of 2026 Federal Changes to the Childhood Immunization Schedule on Chronic Hepatitis B Virus Infections in the United States.

Annals of internal medicine·2026

Regulatory-Driven Pharmacokinetic and Immunogenicity Study of Siltartoxatug, a Recombinant Native Human Monoclonal Antibody Against Tetanus Toxin, in Cynomolgus Monkeys.

Advances in pharmacological and pharmaceutical sciences·2026

The impact of an adaptive patient-centered web application on medication optimization in patients with HFrEF: Rationale and design of the SmartHF trial.

American heart journal plus : cardiology research and practice·2026

Non-eligibility for highly effective modulator therapy with elexacaftor/tezacaftor/ivacaftor in cystic fibrosis: What about Portugal?

Pulmonology·2026

Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.

European journal of neurology·2026

Novel Technologies and Clinical Breakthroughs: The Evolving Landscape of Gene Therapy in China.

Human gene therapy·2026

Advances in the Role of Chemokines in Microwave Ablation-Based Combinatorial Immunotherapy.

Cancer science·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us